Fiche centre
Shenzhen People's Hospital
Shenzhen — China
Essais liés5clinical trials
VilleShenzhenlocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06875310
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Adagrasib | Cancer | Phase 3 | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING |
| Anisodine Hydrobromide | Migraine | Phase 3 | NCT05416476 | ATEM — Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine | UNKNOWN |
| Donanemab | Alzheimer | Phase 3 | NCT07571161 | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | RECRUITING |
| SG301 SC Injection | Lupus | Phase 1 | NCT06144710 | SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus | COMPLETED |
| Litifilimab | Lupus | Phase 3 | NCT05352919 | EMERALD — An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | ENROLLING_BY_INVITATION |